# Tezepelumab and Methacholine Airway Hyperresponsiveness in Participants With Mild Allergic Asthma

> **NCT05740748** · PHASE2 · UNKNOWN · sponsor: **McMaster University** · enrollment: 34 (estimated)

## Conditions studied

- Asthma, Allergic

## Interventions

- **DRUG:** Tezepelumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05740748
- **Lead sponsor:** McMaster University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-04-01
- **Primary completion:** 2024-12-30
- **Final completion:** 2024-12-30
- **Target enrollment:** 34 (ESTIMATED)
- **Last updated:** 2023-02-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05740748

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05740748, "Tezepelumab and Methacholine Airway Hyperresponsiveness in Participants With Mild Allergic Asthma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05740748. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*